– UK, Burton on Trent – Clinigen Group plc (AIM: CLIN), the global pharmaceutical and services company, announces a number of Board changes.
- Chris Rigg today joins as an executive director with immediate effect, having previously served as Chief Executive of Quantum Pharma Plc (“Quantum”);
- Anne Hyland joins as a non-executive director with effect from 1 January 2018;
- Peter George and John Bacon, are stepping down with immediate effect.
Chris Rigg was appointed as CEO of Quantum in October 2016 having previously served as Quantum’s CFO and Strategy Director. Prior to Quantum, Chris was CEO of NRG, a national recruitment agency and prior to that he was head of Barclays Bank’s North East large corporate banking division. Previously, he worked at EAGA plc, the UK support services group, and in corporate finance with Deloitte. He qualified as a chartered accountant with PwC.
Anne is CFO of Kymab Ltd, a private biopharmaceutical company. She is also a non-executive director of Elementis plc, a global specialty chemicals company. Previously, she was CFO of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc. Prior to her role at Vectura, Anne held a number of senior finance positions at Celltech Group plc, Medeva plc and KPMG. She is a qualified chartered accountant (FCA), and corporate tax adviser (CTA – AITI).
Anne will become chair of the Audit and Risk Committee.
Peter Allen, Chairman said: “We are delighted to welcome Chris and Anne. Chris has extensive relevant experience from his executive roles; Anne has significant experience from both her executive and her non-executive positions.
“On behalf of everyone at Clinigen, I want to thank Peter. As we said last year when he stepped down as CEO, Peter has done a tremendous job developing and growing Clinigen. Since then, as a non-executive director, he has been a major support to the Board.
“Also, I’d like to thank John. He has made a valuable contribution following the acquisition of Link, through his expertise in the Africa and Asia Pacific markets.
“We wish both Peter and John well.”
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information : https://www.clinigengroup.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
